This Article Abstract Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Montalescot, G. Search for Related Content PubMed Articles by Montalescot, G. Related Collections Related Article

Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention

1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial

Gilles Montalescot, MD, PhD^_*,_*, Richard Gallo, MD, Harvey D. White, MB, ChB, DSc, Marc Cohen, MD, Ph. Gabriel Steg, MD^||, Philip E.G. Aylward, MB, ChB, PhD^¶, Christoph Bode, MD, PhD^#, Massimo Chiariello, MD^_**, Spencer B. King, III, MD, Robert A. Harrington, MD, Walter J. Desmet, MD, Carlos Macaya, MD, PhD^||||, Steven R. Steinhubl, MD^¶¶,## for the STEEPLE Investigators

^_* Institut du Cœur, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
The Montreal Heart Institute, University of Montreal, Montreal, Canada
Auckland City Hospital, Auckland, New Zealand
Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey
^|| INSERM U-698, Université Paris 7 and AP-HP, Paris, France
^¶ Cardiology Research, Flinders Medical Centre, South Australia, Australia
^# Abteilung Innere Medizin III, Universitätsklinikum Freiburg, Freiburg, Germany
^_** Division of Cardiology, Federico 2nd University, Naples, Italy
St Joseph's Heart and Vascular Institute, Atlanta, Georgia
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
University Hospital Gasthuisberg, Leuven, Belgium
^|||| Servicio de Cardiología, Hospital Universitario, Madrid, Spain
^¶¶ Geisinger Clinic, Geisinger Center for Health Research, Danville, Pennsylvania
^## The Medicines Company, Zurich, Switzerland

View larger version (19K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Kaplan-Meier Survival Curves for All-Cause Mortality According to Study Treatment Kaplan-Meier survival curves for enoxaparin (Enox) 0.50 mg/kg and 0.75 mg/kg, and unfractionated heparin (UFH) treatment groups showing (A) landmark analysis of all-cause mortality starting at day 30 post-randomization; and (B) all-cause mortality from randomization to 1 year.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Figure 2 All-Cause Mortality Rates According to the Occurrence of Initial Ischemic or Bleeding Complications All-cause mortality rates at 1 year in patients who did, or did not experience the following events: (A) nonfatal myocardial infarction (MI) or urgent target vessel revascularization (UTVR); (B) increased creatine kinase (CK) levels or creatine kinase-myocardial/brain mass (CK-MB) fraction release; and (C) major bleeding. ULNR = upper limit of the normal range.

View larger version (14K): [in this window] [in a new window] [Download PPT slide]   Figure 3 Risk Factor Analysis for All-Cause Mortality at 1 Year ASA = aspirin; CI = confidence interval; HR = hazard ratio; PCI = percutaneous coronary intervention; other abbreviations as in Figure 2.